← Back to Search

PARP Inhibitor

Olaparib for Prostate Cancer

Phase 2
Waitlist Available
Led By Michael Schweizer
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is testing olaparib to see if it can stop the growth of prostate cancer cells that are resistant to castration by blocking some of the enzymes needed for cell growth.

Eligible Conditions
  • Prostate Adenocarcinoma
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Lowest on-treatment prostate specific antigen (PSA)
Overall response rate (ORR)
Secondary outcome measures
Incidence and severity of adverse events
Overall survival
PSA PFS
+2 more

Side effects data

From 2023 Phase 3 trial • 154 Patients • NCT02184195
49%
Nausea
47%
Fatigue
38%
Diarrhoea
29%
Abdominal pain
29%
Anaemia
28%
Constipation
27%
Decreased appetite
27%
Back pain
26%
Vomiting
21%
Arthralgia
19%
Pyrexia
18%
Asthenia
13%
Rash
13%
Nasopharyngitis
11%
Alanine aminotransferase increased
11%
Dyspnoea
10%
Neuropathy peripheral
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Anxiety
10%
Pruritus
9%
Hyperglycaemia
9%
Aspartate aminotransferase increased
9%
Dizziness
9%
Thrombocytopenia
9%
Oedema peripheral
9%
Pain in extremity
9%
Insomnia
9%
Stomatitis
9%
Dry mouth
9%
Headache
9%
Neutropenia
8%
Blood creatinine increased
8%
Weight decreased
7%
Dysgeusia
7%
Blood alkaline phosphatase increased
7%
Neutrophil count decreased
7%
Muscle spasms
7%
Influenza
7%
Influenza like illness
7%
Myalgia
7%
Peripheral sensory neuropathy
7%
Gamma-glutamyltransferase increased
6%
Hypertension
6%
Platelet count decreased
6%
Depression
6%
Lymphopenia
6%
Gastrooesophageal reflux disease
6%
Abdominal distension
5%
Musculoskeletal pain
3%
Flank pain
2%
Cholangitis
2%
Flatulence
2%
Paraesthesia
1%
General physical health deterioration
1%
Bladder papilloma
1%
Pneumonia pneumococcal
1%
Abdominal infection
1%
Bartholinitis
1%
Pneumonia
1%
Cerebrovascular accident
1%
Pneumothorax
1%
Gastric varices haemorrhage
1%
Large intestinal obstruction
1%
Cholecystitis
1%
Anastomotic haemorrhage
1%
Device occlusion
1%
Stent malfunction
1%
Bronchiolitis
1%
Empyema
1%
Syncope
1%
Incisional hernia
1%
Device dislocation
1%
Obstruction gastric
1%
Cardiac failure
1%
Vascular stenosis
1%
Pleural effusion
1%
Incarcerated inguinal hernia
1%
Urinary tract infection
1%
Hypothyroidism
1%
Transient ischaemic attack
1%
Infusion related reaction
1%
Duodenal perforation
1%
Melaena
1%
Bile duct obstruction
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaparib 300 mg Twice Daily (bd)
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (Olaparib)Experimental Treatment1 Intervention
Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Olaparib
2007
Completed Phase 4
~2140

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,738 Previous Clinical Trials
1,844,349 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,259 Previous Clinical Trials
288,593,900 Total Patients Enrolled
Michael SchweizerPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium
10 Previous Clinical Trials
142 Total Patients Enrolled

Media Library

Olaparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04951492 — Phase 2
Prostate Adenocarcinoma Research Study Groups: Treatment (Olaparib)
Prostate Adenocarcinoma Clinical Trial 2023: Olaparib Highlights & Side Effects. Trial Name: NCT04951492 — Phase 2
Olaparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04951492 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are currently enrolled in this research project?

"That is correct. The listing on clinicaltrials.gov indicates that the research team is currently enrolling patients. This trial was first advertised on November 25th, 2022 and updated as recently as October 25th, 2022. They are looking for 30 individuals across 1 study site."

Answered by AI

What other research is there in this area?

"There are 197 clinical trials worldwide that are still recruiting patients for Olaparib. These studies began as early as 2005 and have been conducted in 59 different countries across 1462 cities."

Answered by AI

What does the current research say about Olaparib's effects?

"Olaparib is currently being investigated in 27 Phase 3 trials as part of a larger pool of 197 clinical studies. Although the majority of these live trials are based in Houston, Texas, there are 9317 locations running these investigations globally."

Answered by AI

What is the goal of this clinical trial?

"According to information provided by the study sponsor, AstraZeneca, the primary objective of this study is to measure Lowest on-treatment prostate specific antigen (PSA) over a period of up to 1 year. Additionally, this study will be measuring secondary outcomes including Radiographic progression free survival (PFS), PSA PFS, and Radiographic response rate."

Answered by AI

What are the negative effects of Olaparib on human health?

"While Phase 2 trials don't have the same efficacy data as later phases, our team believes that Olaparib is safe enough to be given a score of 2."

Answered by AI

Are there still vacancies in this experiment for people who want to participate?

"That is right, the listing on clinicaltrials.gov says that the research team responsible for this project are actively looking for patients to enroll. This study was made public on November 25th, 2020 and updated October 25th, 2020. They are hoping to have 30 people join from 1 locations."

Answered by AI

What are the primary indications for Olaparib?

"Olaparib is most commonly used as a treatment for ovarian cancer, primary peritoneal cancer, and other conditions such as hallucinations and somatic disorders."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
2022. "Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04951492.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top